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Introduction: Hepatitis B virus (HBV) flare is a serious problem following hematopoietic stem cell transplantation
(HSCT), and the mortality rate is high if severe hepatitis occurs.
Case description: Although Entecavir (ETV) is a standard antiviral drug for HBV infection, the efficacy and safety of
ETV therapy in HSCT are still unclear.
Discussion and Evaluation: To examine the efficacy and tolerability of ETV treatment in HSCT, we retrospectively
identified 5 patients who received ETV for treatment of HBsAg carrier among patients undergoing HSCT in our
institute. We reviewed their clinical information such as clinical course of serum HBV DNA levels, administration
period and dose of ETV, and adverse events. There were no episodes of HBV flare or reactivation after HSCT in all
patients during the observation period, as a 10-fold rise in HBV DNA levels or positive conversion of HBsAg were
not observed.
Conclusion: ETV monotherapy is effective and safe for HBsAg carrier patients following HSCT.
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Hepatitis B virus (HBV) flare and reactivation after
hematopoietic stem cell transplantation (HSCT) is a life-
threatening complication in patients with HBV infection
(Liang et al. 1999). HBV related hepatitis is generally ob-
served in hepatitis B surface antigen (HBsAg)-positive
and/or HBV DNA-positive patients (Hui et al. 2005). Re-
cently, however, HBV reactivation was reported in pa-
tients with even though resolved HBV infection that was
indicated negative HBsAg and positive anti-hepatitis B
core antibody (HBcAb) and/or HBsAb) at a lower rate
(Knoll et al. 2004). It is well established that the fre-
quency of HBV reactivation is higher in HSCT patients
(Hammond et al. 2009). The underlying mechanism of
HBV flare and reactivation following HSCT is likely to
be related to impaired cellular immunity caused by prior
chemotherapy and conditioning regimens. Furthermore,* Correspondence: kkimura@cick.jp
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in any medium, provided the original work is padministration of immunosuppressive agents, including
calcineurin inhibitors and steroids for graft-versus-
host disease (GVHD), may exacerbate HBV replication
(Xunrong et al. 2001).
HBV-infected patients at high risk of HBV flare and
reactivation are recommended to receive preemptive
antiviral therapy following HSCT. Lamivudine (LAM),
an analogue of cytidine, is available for antiviral therapy
in HSCT, (Tomblyn et al. 2009) and inhibits HBV re-
verse transcriptase, resulting in suppression of HBV
replication. Several studies have reported the efficacy of
LAM treatments in HSCT patients (Hsiao et al. 2006;
Giaccone et al. 2010).
However, LAM treatment has the potential to induce
development of drug-resistant mutations owing to the
low genetic barrier. Since a small number of mutations
are required for LAM resistance, the incidence of LAM-
resistant HBV has recently been increasing, and LAM
resistance is associated with a rebound in viral load and
hepatitis. In fact, LAM treatments showed high resist-
ance and recurrence rates in patients with chronicOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ation (Perrillo et al. 2001; Mutimer et al. 2000; Lo et al.
2001). Similarly, the appearance of drug-resistant mutants
and HBV DNA breakthrough within LAM treatments has
been reported in HSCT patients (Hsiao et al. 2006). Thus,
more effective agents with lower resistance rates are re-
quired in both liver transplantation and HSCT.
Entecavir (ETV), a cyclopentyl guanosine nucleoside
analogue, has been approved for treatment of patients
with CHB. ETV inhibits reverse transcriptase, DNA rep-
lication and transcription. Compared with LAM, ETV
has greater antiviral potency and a higher genetic barrier
to resistance (Lai et al. 2002). Several studies have shown
the superiority of ETV treatments in liver transplant-
ation (Xi et al. 2009; Fung et al. 2011), however, ETV
treatment for patients undergoing HSCT has not been
reported, and its role in HSCT remains unclear. Here,
we describe HBsAg carrier patients administered ETV




This study was approved by the local medical ethics com-
mittee of Tokyo Metropolitan Komagome Hospital. We
retrospectively identified HBsAg carrier patients (serum
HBsAg-positive and HBV-DNA positive) who received
ETV for prophylaxis of HBV flare among patients under-
going HSCT between September 2006 and August 2011.
We Laboratory data and clinical information were ob-
tained from our institution’s electronic medical records.
Hematopoietic stem cell transplantation methods
In our institution, myeloablative conditioning regimens
were administered to allogeneic recipients aged <60 years,
while elderly patients received fludarabine-based reduced-
intensity regimens. GVHD prophylaxis usually comprised
short-course methotrexate and cyclosporine A (CsA) or
tacrolimus (FK506). For acute GVHD treatment, methyl-
prednisolone (mPSL) 2 mg/kg i.v. in divided dose daily
was administered. Antibacterial prophylaxis was provided
by tosufloxacin. Steroid-resistant GVHD was treated with
a steroid pulse (mPSL 1000 mg i.v. in divided dose daily
for 3 days) or mycophenolate mofetil (MMF) 1000 mg
twice daily p.o.. Antifungal prophylaxis consisted of flu-
conazole or itraconazole. Acyclovir or valacyclovir was ad-
ministered for herpes simplex virus prophylaxis and
ganciclovir or foscarnet was administered against cyto-
megalovirus reactivation.
Entecavir therapy
ETV 0.5 mg once daily p.o. was administered to patients
with HBsAg-positive as primary treatments. The ETV
dose was adjusted according to the kidney function.None of the patients received LAM or hepatitis B im-
munoglobulin at the time of transplantation or during
the post-transplant period.
Hepatitis B virus assay
The levels of HBsAg, anti-HBc and anti-HBs were de-
termined using commercially available chemilumines-
cence enzyme immunoassay kits (LUMIPULSE Presto
HBsAg, LUMIPULSE Presto HBsAb-N, LUMIPULSE
Presto HBcAb-III; Fujirebio, Tokyo, Japan). The cut-off
index (COI) of the assay of HBsAg, anti-HBs and anti-
HBc was 1.0, 10 mIU/mL and 1.0, respectively. The
serum HBV DNA concentrations were quantified using
the COBAS AmpliPrep/COBAS TaqMan HBV Test
(Roche Diagnostics, Basel, Switzerland). The four major
HBV genotypes (A–D) were determined by enzyme-linked
immunosorbent assay with monoclonal antibodies directed
against distinct epitopes on the preS2-region products
using commercial kits (HBV GENOTYPE EIA; Institute of
Immunology Co. Ltd., Tokyo, Japan) (Orito et al. 2001).
HBV DNA sequences bearing the core promoter and
precore or core regions were amplified by PCR with
heminested primers. The PCR products were directly
sequenced by the dideoxy chain termination method
using a Big Dye Terminator (Applied Biosystems, Foster
city, CA) and an ABI PRISM 3100-avant analyzer
(Aritomi et al. 1998).
Case description
Patient profiles
Among the 376 patients who received HSCT in our hos-
pital between September 2006 and August 2011, six
HBsAg-positive and HBV-DNA positive patients were
identified (Figure 1). Of those patients, five patients re-
ceived ETV for prevention of HBV flare (Table 1). Four
patients were inactive chronic hepatitis B (ICHB) (#1,
#2, #4 and #5) and other patients were CHB (#3), re-
spectively. Patient #5 has developed HBV reactivation
during pre-transplantation therapy at previous treated
hospital. Four patients underwent allogeneic HSCT,
while one patient underwent autologous HSCT (#1).
Within 4 allogeneic recipients, patient #4 received a
graft from a matched related donor, while the other
three patients received grafts from matched unrelated
donors. All of donors were serum HBsAg negative. Mye-
loablative conditioning regimens were administered to
three allogeneic recipients and a fludarabine-based non-
myeloablative conditioning regimen was administered to
the remaining allogeneic recipient. For GVHD prophy-
laxis, one patient (#2) received CsA and methotrexate
and three patients received FK506 and methotrexate. At
the time of transplantation, two patients had undetect-
able serum HBV DNA levels. Three patients were HBV
genotype C and one patient was genotype B. In addition,
376 HSCT patients enrolled from 2006 to 2011
6 patients with HBsAg positive
5 patients treated with Entecavir
1 patients treated with Lamivudine
370 patients excluded with 
HBsAg negative
Figure 1 Flow of study participants.
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tected in all patients (Table 2).
ETV administration can prevent HBV flare and
reactivation following HSCT.
The median observation period was 12.5 months (range,
2–50 months). ETV 0.5 mg once daily p.o. was adminis-
tered as primary treatments for HBV infection. The ETV
dose was increased after HSCT with patient #4 due to ele-
vation of HBV viral load. Nevertheless all allogeneic-
HSCT recipients suffered from mucous membrane dis-
order, no patient discontinue ETV oral administration. #4
and #5 patients developed renal disorder due to toxoplas-
mosis and adverse event of FK506 respectively. The ETV
doses were reduced according to the kidney function in
these patients. ETV was well tolerated in all cases and no
patients discontinued ETV during the follow-up period
for severe adverse events. There was no adverse drug
interaction between ETV and other drugs. Median neutro-
phil engraftment time was 20 days (range 16–32 days) in
allogeneic HSCT patients (#2-5). No cytopenia due to
ETV treatment was observed in all patients. At the last
follow-up, three patients (#1, #2 and #4) had died and theTable 1 Characteristics of 5 HSCT recipients treated with Ente
Case Age
(y)




#1 64 F MM Autologous (−) No
#2 55 F MDS-RAEB Allogeneic FK + MTX Yes
#3 24 F MDS-
RCMD
Allogeneic FK + MTX Yes
#4 58 F AML Allogeneic CsA + MTX Yes
#5 63 F T-LBL Allogeneic FK + MTX Yes
Abbreviation: MM multiple myeloma, MDS myelodysplastic syndrome, RAEB refracto
dysplasia, AML acute myeloid leukemia, T-LBL T lymphoblastic lymphoma, FK tacroli
CY cyclophosphamide, TBI total body irradiation, Flu fludarabine.causes of mortality were aspergillus pneumonia, aggrava-
tion of underlying disease and toxoplasmosis, respectively.
In respect to immunosuppressive agent, two patients
(#4 and #5) received mPSL 2 mg/kg i.v. in divided dose
daily for acute GVHD in a short period. Patients #2 and
#3 suffered chronic GVHD and continued to receive sys-
temic steroid (mPSL 0.5 mg/kg and PSL 0.5 mg/kg i.v.
in divided dose daily, respectively) and FK506 for the ob-
servation period. Patient #2 received a steroid pulse
(mPSL 1000 mg i.v. in divided dose daily for 3 days)
against exacerbation of chronic GVHD. Nevertheless,
steroid treatment continued during GVHD in these pa-
tients and HBV DNA was not detected, indicating that
ETV effectively protected against HBV flare and reacti-
vation. In patients #3 and #4, MMF was also added for
steroid-refractory GVHD.
There were no episodes of HBV flare or reactivation
after HSCT in all patients during the observation period,
as a 10-fold rise in HBV DNA levels or positive conver-
sion of HBsAg were not observed. As shown in Figure 2,
although patient #3 showed a significantly high HBV
DNA level during the HSCT period, HBV flare was not








- Mel 2 M Dead MM
Yes BU + CY 9 M Dead Aspergillus
Pneumonia
Yes BU + CY 50 M Alive -
No BU + CY 4 M Dead Toxoplasmosis
No Flu + Mel +
TBI(4Gy)
16 M Alive -
ry anemia with excessive blast, RCMD refractory cytopenia with multilineage
mus, CsA ciclosporin A, Mel melfalan, BU busulfan,
Table 2 HBV markers of 5 HSCT recipients treated with Entecavir
Case Genotype HBsAg HBsAb HbcAb BCP/Precore Initial serum HBV DNA (xLog Copies/ml) Flare after HSCT
#1 ND (+) (−) (+) ND 4 No
#2 C (+) (−) (+) ND Undetectable No
#3 B (+) (−) (+) Wild type >7.6 No
#4 C (+) (−) (+) Wild type Undetectable No
#5 C (+) (−) (+) Wild type 7.4 No
Abbreviation: BPC basal core promoter, ND not determined.
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tient #3 showed reduction of HBV DNA to an undetect-
able level at the last follow-up.Discussion and evaluation
A phase III trial reported that ETV has superior viro-
logical, histological and biochemical efficacy as an anti-
viral drug for HBV infection compared with LAM
(Chang et al. 2006). Furthermore, ETV showed a low re-
sistance rate compared with LAM (Tenney et al. 2009).
Recent case reports have described successful treatment
of HBV reactivation after HSCT with ETV (Christopeit
et al. 2010; Milazzo et al. 2011). Therefore, ETV is aFigure 2 Clinical courses of HSCT patients treated with ETV. The X-axi
DNA copy numbers, respectively. Transitions of HBsAg and HBsAb are show
#3. HBV DNA of patient #3 became detectable level transiently. ALT elevati
Causes of ALT elevation were considered GVHD or VOD.strong candidate as a substitute for LAM for HBV
prophylaxis in HSCT.
The present study has shown the safety and efficacy of
ETV treatment for protection against HBV flare after
HSCT. Similar to previous reports for liver transplant-
ation, (Fung et al. 2011) all the patients continued ETV
through to the last follow-up without any intolerable ad-
verse events. Intense immunosuppression during HSCT
owing to the conditioning regimen and GVHD prophy-
laxis is a serious risk for HBV flare and reactivation.
However, no HBV flare after HSCT was documented
during our observation period with ETV treatment. Al-
though blood count after HSCT is not stable, no cytope-
nia due to ETV was observed. Furthermore, no drugs shows the time course, and the Y-axes show the ALT levels and HBV
n at the top. No HBV DNA elevation was observed except for patient
on after HSCT was observed in all allogeneic HSCT recipients (#2-5).
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study has demonstrated that ETV treatment is a promis-
ing candidate for HBV flare and reactivation prophylaxis
in HSCT, similar to the case for liver transplantation.
Seroclearance of HBsAg and HBV DNA was observed
with patient #3, despite a high HBV DNA level during
the HSCT period. The timing of the serum HBsAg clear-
ance was consistent with that in a liver transplantation
study (Fung et al. 2011). Of the 5 patients tested, HBsAb
was detectable with 1 patient (#3). The time of detection
of HBsAb was 6 weeks after HSCT. HBsAb with patient
#3 was detectable during the follow-up period. This
positive conversion of HBsAb might be associated with
HBsAg clearance (Fung et al. 2011).
All allogeneic HSCT patients showed serum ALT ele-
vation after HSCT. Almost all cases showed ALT eleva-
tion without HBV DNA elevation or positive conversion
of HBsAg, and we considered that these liver injuries
were caused by GVHD or drug-induced hepatotoxicity.
Serum ALT elevation and positive conversion of HBV
DNA were observed at the same time with patient #3 at
17 months after the HSCT period. However, chronic
GVHD symptoms, such as skin keratinization and oral
dryness, were exacerbated around the same time and
ALT decreased after systemic steroid and MMF adminis-
tration. Moreover, the positive reaction for HBV DNA
was transient and the presence of HBsAg conversely be-
came negative. Collectively, based on these findings, we
suggest that the ALT elevation might have been caused
by chronic GVHD.
There are some limitations in this study, since it was
retrospective and the number of patients was small. Half
of the patients died within 1 year after HSCT and their
observation periods were insufficient. In future, a large
prospective study of ETV prophylaxis in HSCT is
required.
Conclusions
In conclusion, our study showed that ETV monotherapy
may be effective and safe after HSCT for patients with
HBV. Our study will contribute to future clinical trials.
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